Company: HQL
Filing Date: 2025-05-29
Form Type: NPORT-P
Source: 0001752724-25-128179
Chunk: 299

Company: abrdn Life Sciences Investors
Filing Date: 2025-05-29
Form: NPORT-P
Chunk 299
---
 and receives collateral. Select "reverse repurchase 
 agreement" if the Fund is the cash borrower and posts collateral.   | Repurchase         
 Reverse repurchase |

b. Counterparty.

| i.	Cleared by central counterparty? [Y/N] If  Y, provide the name of the central counterparty. | Yes 
 No  |

ii. If N, provide the name and LEI (if any) of counterparty.

| c. Tri-party?       | Yes 
 No  |
| d. Repurchase rate. |     |
| e. Maturity date.   |     |

f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

Item C.11. For derivatives, also provide:

| a. Type of derivative instrument that most closely                  
 represents the investment, selected from among the following        
 (forward, future, option, swaption, swap (including but not limited 
 to total return swaps, credit default swaps, and interest rate      
 swaps), warrant, other).                                            | Other  |
| If "other", provide a brief description.                            | rights |

b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

| Counterparty Record:		1       |     |
| Name of counterparty.         | N/A |
| LEI (if any) of counterparty. | N/A |

3. If the reference instrument is neither a derivative or an index, the description of the reference instrument shall include the name of issuer and title of issue, as well as CUSIP of the reference instrument, ISIN (if CUSIP is not available), ticker if (CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).

| Name of issuer. | Tetraphase Pharmaceuticals Inc |
| Title of issue. | Tetraphase Pharmaceuticals Inc |

At least one of the following other identifiers:

| Identifier. | CUSIP     |
| CUSIP.      | 88165N105 |

| Identifier.                       | ISIN (if CUSIP is not available) |
| ISIN (if CUSIP is not available). | US88165N1054                     |

| ii.	Termination or maturity (